The product indicated a statistically significant improvement in the signs and symptoms of Ankylosing Spondylitis
, as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40 (ASAS40) response at 16 weeks, when compared to placebo.
is an inflammatory condition that affects the joints of the spine, reducing its flexibility, damaging the posture and posing the risk of loss of mobility.
Minireview: HLA-B27 and its immunogenetics in ankylosing spondylitis
Disease activity was measured on the Bath Ankylosing Spondylitis
Disease Activity Index.
Sacroiliitis and spondylitis with sternoclavicular hyperostosis: SAPHO or an ankylosing spondylitis
Keywords: Stress test, Patellofemoral pain syndrome, Ankylosing spondylitis
, Case report.
Osteopontin might be involved in bone remodeling rather than in inflammation in ankylosing spondylitis
The BASDAI was used to evaluate clinical disease activity, while the Bath Ankylosing Spondylitis
Functional Index (BASFI) was used to determine disease-related functional insufficiency [30,31].
The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis
Out of these, Ankylosing Spondylitis
(AS) was diagnosed in 32 (5.
6,7) Only a few reports, however, concerning the use of cementless THA in ankylosing spondylitis
has been published.
USPRwire, Mon Dec 14 2015] Global Markets Direct's, 'Ankylosing Spondylitis
(Bekhterev's Disease) - Pipeline Review, H2 2015', provides an overview of the Ankylosing Spondylitis
(Bekhterev's Disease)'s therapeutic pipeline.
DENVER -- Even as prescribing of tumor necrosis factor inhibitors for patients with ankylosing spondylitis
climbed in the last half-dozen years, patients' use of prescription narcotics increased as well.
is a chronic inflammatory disease that predominantly affects the dorsal column, the inflammatory process starting frequently at the level of sacroiliac joints and progressing upwardly.
8 mL (adalimumab; [genetical recombination], "HUMIRA"), a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis